L-type blocker STIMulate Ca²⁺ entry in synthetic VSMCs

Affiliations

¹ Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, 69120, Germany. Electronic address: marc.freichel@pharma.uni-heidelberg.de.
² Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, 69120, Germany.

Comment

Marc Freichel et al. Cell Calcium. 2020 Nov.

. 2020 Nov:91:102279.

doi: 10.1016/j.ceca.2020.102279. Epub 2020 Aug 28.

¹ Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, 69120, Germany. Electronic address: marc.freichel@pharma.uni-heidelberg.de.
² Pharmakologisches Institut, Ruprecht-Karls-Universität Heidelberg, 69120, Heidelberg, Germany; DZHK (German Centre for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Heidelberg, 69120, Germany.

No abstract available

Keywords: Amlodipine; L-type calcium channel; LTCCB; STIM; Synthetic vascular smooth muscle cells.

Comment on

L-type Ca²⁺ channel blockers promote vascular remodeling through activation of STIM proteins.
Johnson MT, Gudlur A, Zhang X, Xin P, Emrich SM, Yoast RE, Courjaret R, Nwokonko RM, Li W, Hempel N, Machaca K, Gill DL, Hogan PG, Trebak M. Johnson MT, et al. Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):17369-17380. doi: 10.1073/pnas.2007598117. Epub 2020 Jul 8. Proc Natl Acad Sci U S A. 2020. PMID: 32641503 Free PMC article.